574
COMPARING EFFICACY OF PRUCALOPRIDE WITH 2-L PEG VERSUS 2-L PEG FOR BOWEL PREPARATION: A RANDOMIZED CONTROLLED TRIAL
Date
May 19, 2024
Explore related products in the following collection:
Background: Studies found prokinetic agents improve preprocedural tolerability and efficacy in bowel cleansing before colonoscopy. We investigated the use of prucalopride for improving the efficacy and tolerability of bowel cleansing prior to colonoscopy.
Method: This was a prospective, single-center, randomized controlled trial that included 162 participants who were randomized to receive either 2-L polyethylene glycol (PEG) + prucalopride (prucalopride group) or 2-L polyethylene glycol (PEG) + placebo (control group). The primary endpoint was the efficacy of colon cleansing assessed by blinded endoscopists using the Boston bowel preparation scale (BBPS) and the Ottawa scale. The efficacy of colon cleansing was also verified by blinded investigators. Acceptability, tolerability, and adenoma detection rate (ADR) of these 2 regimens were secondary endpoints.
Results: A better score preparation was observed in the prucalopride group than in the PEG group for both the Boston bowel preparation scale, right side (2.81 vs 2.01, P < 0.001), transverse (2.91 vs 2.25, P < 0.001), left side (2.9 vs 2.37, P < 0.001) and total (8.63 vs 6.56, P < 0.001) and Ottawa scale, right side (0.19 vs 1.05, P < 0.001), transverse (0.09 vs 0.75, P < 0.001), left side (0.1 vs 0.7, P < 0.001) and total (0.37 vs 2.51, P < 0.002, table 1). There were no statistically significant differences between the groups in ADR and patient satisfaction. Adverse reactions were not different between the groups.
Conclusions: Prucalopride may be an effective and safe adjunct to PEG that leads to an improved quality of bowel preparation.
Method: This was a prospective, single-center, randomized controlled trial that included 162 participants who were randomized to receive either 2-L polyethylene glycol (PEG) + prucalopride (prucalopride group) or 2-L polyethylene glycol (PEG) + placebo (control group). The primary endpoint was the efficacy of colon cleansing assessed by blinded endoscopists using the Boston bowel preparation scale (BBPS) and the Ottawa scale. The efficacy of colon cleansing was also verified by blinded investigators. Acceptability, tolerability, and adenoma detection rate (ADR) of these 2 regimens were secondary endpoints.
Results: A better score preparation was observed in the prucalopride group than in the PEG group for both the Boston bowel preparation scale, right side (2.81 vs 2.01, P < 0.001), transverse (2.91 vs 2.25, P < 0.001), left side (2.9 vs 2.37, P < 0.001) and total (8.63 vs 6.56, P < 0.001) and Ottawa scale, right side (0.19 vs 1.05, P < 0.001), transverse (0.09 vs 0.75, P < 0.001), left side (0.1 vs 0.7, P < 0.001) and total (0.37 vs 2.51, P < 0.002, table 1). There were no statistically significant differences between the groups in ADR and patient satisfaction. Adverse reactions were not different between the groups.
Conclusions: Prucalopride may be an effective and safe adjunct to PEG that leads to an improved quality of bowel preparation.
Table 1 Successful cleansing rates according to colonic segment
Tracks
Related Products
COMPARISION OF 1 DAY VERSUS 5 DAYS OF OCTREOTIDE INFUSION ALONG WITH ENDOSCOPIC THERAPY IN PREVENTING EARLY REBLEEDING AND MORTALITY FROM ESOPHAGEAL VARICES: A NATIONWIDE, MULTICENTER, NON-INFERIORITY, RANDOMIZED CONTROL TRIAL - PRELIMINARY RESULT
Variceal bleeding represents a critical complication with high mortality. Baveno VII recommends vasoactive agents to achieve hemostasis and prevent rebleeding. However, an optimal shorter time frame limit for vasoactive drug therapy remains unclear, and no specific duration is mentioned…
